Pharmacokinetics, safety, tolerability, and immunogenicity of FKB238, a new biosimilar of bevacizumab, in healthy participants

Boyce, M; Wilkes, D; Kaito, H; Takanuma, M; Arai, Y

Boyce, M (通讯作者)，Hammersmith Med Res Ltd, Cumberland Ave, London NW10 7EW, England.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2022; 60 (6): 280

Abstract

Objective: To compare the and immunogenicity of single intravenous doses of FKB238, a proposed biosimilar of approved and United States (US)-licensed ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索